Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

PRA

- PMLiVE

Ipsen announces launch of new UK headquarters in London life sciences community

The Paddington site will serve as one of the company’s three global hubs

- PMLiVE

Takeda gains rights to Kumquat’s immune-oncology programme in deal worth over $1.2bn

The selected candidate can be developed as a monotherapy, combination therapy or both

- PMLiVE

Takeda’s Takhzyro granted MHRA approval for younger hereditary angioedema patients

The rare genetic disorder is estimated to affect one in every 50,000 people

- PMLiVE

Takeda’s HyQvia receives MHRA approval for rare neurological disorder CIDP

The therapy offers patients with CIDP a typical dosing interval of four weeks

- PMLiVE

Takeda’s Iclusig combination granted FDA accelerated approval for rare form of leukaemia

The drug is now the first targeted therapy approved as a frontline treatment for Ph-positive ALL

- PMLiVE

ABPI sets out UK life sciences industry’s priorities for government’s budget

The ABPI highlights four key areas where the budget could boost UK life sciences

- PMLiVE

Takeda’s Eohilia approved by FDA as first oral therapy for eosinophilic oesophagitis

The inflammatory disease affects around one in 2,000 people in the US

- PMLiVE

Takeda gains rights to Protagonist’s blood disorder asset in deal worth over $300m

Rusfertide is currently being evaluated in a phase 3 clinical trial to treat polycythaemia vera

- PMLiVE

Takeda’s HyQvia receives EC approval for rare neuromuscular disorder CIDP

HyQvia can now be used as a maintenance therapy for patients of all ages with CIDP

- PMLiVE

Takeda’s HyQvia granted FDA approval to treat rare neuromuscular disorder CIDP

Approximately five to seven people per 100,000 in the US are affected by the disorder

- PMLiVE

UK’s Autumn Budget details measures to boost life sciences sector

The new budget will aim to advance research and manufacturing in the UK

- PMLiVE

ABPI report shows improvement in UK industry clinical trial performance

The data showed a 15% increase in annual recruitment to UK industry clinical trials

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links